Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351991 | 0.91 | ALDH1A1 (0.35) | PDE9AALDH1A1POLBPDGFRAPDGFRB | |
| SCHEMBL351556 | 0.88 | ADORA2A (0.37) | EGFRPOLBPDGFRAPDGFRBRAB9A | |
| SCHEMBL350165 | 0.82 | TNNI3K (0.38) | ADORA3ADORA1ADORA2AGPR183 | |
| SCHEMBL351023 | 0.76 | ADORA3 (0.45) | MAPTHTTSMN1; SMN2ADORA3ADORA1 | |
| SCHEMBL370217 | 0.76 | ADORA3 (0.34) | ADORA3ADORA1ADORA2AGPR183 | |
| SCHEMBL1306599 | 0.75 | ALK (0.49) | — | |
| SCHEMBL4412618 | 0.74 | EGFR (0.49) | PDE9AEGFRMEN1KMT2AMAPT | |
| SCHEMBL10171936 | 0.70 | ADORA3 (0.55) | EGFRNPC1RAB9ALMNAHTT | |
| SCHEMBL352724 | 0.68 | SYK (0.37) | EGFRPDGFRAPDGFRBDYRK3MAP4K4 | |
| SCHEMBL1306926 | 0.67 | IRAK4 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960372-B1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | claimed |
| EP-1960372-A1 | KINASE INHIBITORS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| WO-2007070872-A1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | claimed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | MIDCAP FINANCIAL TRUST | 2016-01-28 | — | — | US | disclosed |
| EP-1960372-B1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | disclosed |
| US-9096542-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | PDE9A 1043/4885EGFR 362/4885MEN1 2835/4885 |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | PDE9A 1043/4885EGFR 362/4885MEN1 2835/4885 |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | PDE9A 697/4885EGFR 262/4885MEN1 3297/4885 |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | PDE9A 1043/4885EGFR 362/4885MEN1 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.